Chemoprevention of prostate cancer with finasteride

Edith D. Canby-Hagino, Timothy C. Brandt, Javier Hernandez, Ian M. Thompson

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention. The association between lifetime exposure to dihydrotestosterone and risk of developing prostate cancer suggests that chemoprevention is possible with 5α-reductase inhibition. The recently completed Prostate Cancer Prevention Trial indicates that chemoprevention is possible with the 5α-reductase inhibitor finasteride. Development of a costeffective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits.

Original languageEnglish (US)
Pages (from-to)899-905
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number7
StatePublished - May 1 2006


  • 5α-reductase
  • Chemoprevention
  • Finasteride
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Chemoprevention of prostate cancer with finasteride'. Together they form a unique fingerprint.

Cite this